## CITATION REPORT List of articles citing

The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

DOI: 10.1038/bjc.2017.222 British Journal of Cancer, 2017, 117, 619-627.

Source: https://exaly.com/paper-pdf/67285058/citation-report.pdf

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Multimodal OCS approaches WTP threshold in UK. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2017</b> , 784, 24-24	0.1	
21	Ovarian Cancer Prevention and Screening. Obstetrics and Gynecology, 2018, 131, 909-927	4.9	76
20	Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). JAMA Oncology, 2018, 4, 190-195	13.4	16
19	Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening. <i>Obstetrics and Gynecology</i> , <b>2018</b> , 132, 1091-1100	4.9	14
18	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. <i>Medicines (Basel, Switzerland)</i> , <b>2018</b> , 5,	4.1	80
17	Ovarian cancer prevention and screening. <b>2018</b> , 331-348		
16	Expression levels of MRP1, GST-pand GSK3@n ovarian cancer and the relationship with drug resistance and prognosis of patients. <i>Oncology Letters</i> , <b>2019</b> , 18, 22-28	2.6	16
15	Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources. <i>journal of applied laboratory medicine, The</i> , <b>2019</b> , 4, 299	- <del>3</del> 10	5
14	High throughput proteomics identifies a high-accuracy 11 plasma protein biomarker signature for ovarian cancer. <i>Communications Biology</i> , <b>2019</b> , 2, 221	6.7	44
13	Ultrasound screening of ovarian cancer. <i>Hormone Molecular Biology and Clinical Investigation</i> , <b>2019</b> , 41,	1.3	2
12	Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	3
11	Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125. <i>Communications Biology</i> , <b>2020</b> , 3, 460	6.7	8
10	Ovarian cancer screening: Current status and future directions. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , <b>2020</b> , 65, 32-45	4.6	34
9	A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. <i>Cancer Prevention Research</i> , <b>2020</b> , 13, 429-442	3.2	3
8	Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	3
7	Prevention of Common Cancers of the Female Genital Tract. <b>2018</b> , 161-185		
6	High throughput proteomics identifies 484 high-accuracy plasma protein biomarker signatures for ovarian cancer.		

## CITATION REPORT

5 Introduction to Cancer Prevention. **2019**, 1-16

4	Assessing the Costs of Screening for Ovarian Cancer in the United States: An Evolving Analysis. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	2
3	A Rapid and Affordable Screening Tool for Early-Stage Ovarian Cancer Detection Based on MALDI-ToF MS of Blood Serum. <i>Applied Sciences (Switzerland)</i> , <b>2022</b> , 12, 3030	2.6	О
2	Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy. <b>2022</b> , 19, 12057		1
1	Evaluation of He4 Use in the Diagnosis of Ovarian Cancer: First and Second Recurrence, and an Analysis of HE4 Concentration during Second- and Third-Line Chemotherapy. <b>2023</b> , 13, 452		О